Calliditas Therapeutics
Kelly Killius, PharmD, BCPS has a diverse work experience in the pharmaceutical and healthcare industry. Currently, in 2022, they are serving as the Field Medical Director at Calliditas Therapeutics AB. Previously, they worked at Boston Medical Center (BMC) from 2008 to present, with roles including Per Diem Pharmacist in Emergency Medicine, Residency Director for PGY2 Emergency Medicine, and Clinical Pharmacy Specialist. From 2018 to 2022, they worked as a Medical Science Liaison in Renal/Cardio at AstraZeneca. Before that, they were the Director Global Health Sciences (Medical Science Liaison) at The Medicines Company from 2016 to 2018. Kelly also has experience as a Clinical Pharmacist in Transplant Intensive Care at UPMC from 2007 to 2008. Kelly started their career as a Critical Care Resident at Mayo Clinic Jacksonville in 2006 and as a Pharmacy Practice Resident at SUNY Upstate Medical University from 2005 to 2006.
Kelly Killius, PharmD, BCPS, obtained their Doctor of Pharmacy degree from the University at Buffalo in 2005. Kelly specialized in pharmacy during their studies. In December 2008, they obtained certification as a Board Certified Pharmacotherapy Specialist from the Board of Pharmacy Specialties.
This person is not in any offices
Calliditas Therapeutics
2 followers
Calliditas Therapeutics AB is a specialty pharmaceutical company based in Stockholm, Sweden. It is focused on developing high quality pharmaceutical products for patients with a significant unmet medical need in niche indications, in which Calliditas can partially or completely participate in the commercialization efforts. Calliditas is focused onthe development and commercialization of the product candidate Nefecon, a unique two step formulation optimized to combine a time lag effect with a concentrated release of the active substance budesonide, within a designated target area. This patented, locally acting formulation is intended for treatment of patients with the inflammatory renal disease IgA nephropathy (IgAN). Calliditas is running a global Phase 3 study within IgAN and aims to commercialize Nefecon in the United States.